TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26367529
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (2.4 g protein/kg/d)
Study: 26367529
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (0.4 g protein/kg/d)
Study: 22518934
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C treatment group (1000 mg d(‐1))
Study: 17410435
Drug: mesalazine, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine, 800 mg bid
Study: 17410435
Drug: mesalazine, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine, 400 mg bid
Study: 17410435
Drug: rifaximin, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifaximin, 200 mg bid
Study: 17410435
Drug: rifaximin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifaximin, 400 mg bid
Study: 3593994
Drug: Domperidone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (0.1 mg X kg‐1 i.v.)
Study: 30297759
Drug: Cooked cream
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked cream of rice cereal (CR)
Study: 30297759
Drug: Cooked cream
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked cream of rice cereal with sugar, nuts, and seeds (CRsns)
Study: 26081100
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg CoQ10 twice daily for 1 week
Study: 19465123
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg capsules in the fed state
Study: 19465123
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg capsules in the fasted state
Study: 8676529
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of TPN
Study: 8676529
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of TPN (decreasing infusion rate by 50% for 1 hour before discontinuation)
Study: 6475824
Drug: Inorganic iron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic iron, 920 mumol (51 mg)
Study: 6475824
Drug: HB iron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB iron, 480 mumol (26 mg)
Study: 6475824
Drug: Inorganic iron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic iron, 610 mumol (34 mg)
Study: 6475824
Drug: Tin, 306
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tin, 306 mumol (36 mg)
Study: 6475824
Drug: Copper, 79
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper, 79 mumol (5 mg)
Study: 31106336
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) defibrillating device
Study: 31106336
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) pacer
Study: 23677249
Drug: Desmopressin melt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin melt (120/240 μg)
Study: 23677249
Drug: Desmopressin tablet
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin tablet (0.2/0.4 mg)
Study: 21843943
Drug: Weekly nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly nab-paclitaxel (150 mg/m2)
Study: 15142029
Drug: Mg(2+)-Cr group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg(2+)-Cr group (2.5 g of Cr daily)
Study: 15142029
Drug: Cr group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr group (2.5 g of Cr daily)
Study: 12074415
Drug: Bupivacaine 0.2%
Normalized name: BUPivacaine 0.2%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.2% with fentanyl 2 microg mL(‐1)
Study: 12074415
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% with fentanyl 2 microg mL(‐1)
Study: 2240994
Drug: Betahistine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (24 mg/day)
Study: 7372228
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg digoxin b.i.d.
Study: 7372228
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg digoxin b.i.d.
Study: 7372228
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg beta-methyl-digoxin b.i.d.
Study: 28071011
Drug: Isocaloric diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric diet plus metformin (IM)
Study: 22282104
Drug: HeartMate II
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeartMate II (HMII) destination therapy (DT)
Study: 18355402
Drug: Postmastectomy radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiotherapy plus systemic therapy (cyclophosphamide, methotrexate, and fluorouracil for premenopausal women; tamoxifen for postmenopausal women)
Study: 12578439
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of methylphenidate (3 times daily)
Study: 10561294
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (non‐XRT group)
Study: 1762298
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine ointment (T)
Study: 31869451
Drug: High-dose gabapentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gabapentin (2700 mg daily) with standard care (hydrocodone and/or acetaminophen progressing to fentanyl as needed)
Study: 31869451
Drug: Low-dose gabapentin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gabapentin (900 mg daily) with methadone
Study: 30343354
Drug: Oral saffron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral saffron supplementation (20 mg/day) for 3 months
Study: 30343354
Drug: Oral saffron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral saffron supplementation (20 mg/day) for 3 months among participants on AREDS supplements
Study: 17686343
Drug: Cytotoxic monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic monoclonal antibodies (MAbs)
Study: 16043407
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate 50 mg bid
Study: 8071837
Drug: BOF-4272 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOF-4272 100 mg
Study: 8071837
Drug: BOF-4272 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOF-4272 200 mg
Study: 8071837
Drug: BOF-4272 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOF-4272 400 mg
Study: 8071837
Drug: BOF-4272 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOF-4272 200 mg (multiple-dose)
Study: 8071837
Drug: Placebo (multiple-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multiple-dose)
Study: 30937510
Drug: Narrative Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Enhancement and Cognitive Therapy (NECT)
Study: 21145258
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day plus placebo (ATV+PLA)
Study: 21145258
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day plus allopurinol 300 mg/day (ATV+ALLO)
Study: 16773859
Drug: Comprehensive assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive assessment followed by treatment
Study: 16773859
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without assessment
Study: 16773859
Drug: Repetitive use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive use of ineffective treatments
Study: 11361264
Drug: Nimesulide alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide alone (100 mg BD)
Study: 11361264
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nimesulide (100 mg) and cetirizine (10 mg)
Study: 11361264
Drug: Cetirizine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine alone (10 mg)
Study: 8395721
Drug: Enoxaparin 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20 mg subcutaneously, administered 2 hours before surgery and each morning for 7 postoperative days (morning group)
Study: 8395721
Drug: Enoxaparin 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20 mg subcutaneously, administered the evening before surgery and postsurgically for 7 days in the evening (evening group)
Study: 3512282
Drug: High-dose budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose budesonide (1600 micrograms per day)
Study: 3512282
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose budesonide (400 micrograms per day)
Study: 3512282
Drug: High-dose budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose budesonide (1600 micrograms per day) during open-label phase
Study: 18156171
Drug: Bortezomib monotherapy
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib monotherapy
Study: 15366798
Drug: Pethidine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.8 mg/kg
Study: 11344193
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg/day
Study: 2736882
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution supplemented with L‐alanyl‐L‐glutamine (Ala‐Gln) and glycyl‐L‐tyrosine (Gly‐Tyr)
Study: 2736882
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution supplemented with alanine and glycine
Study: 4881071
Drug: Tetracycline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (3 g or 4 g in one of 3 dose schedules)
Study: 31383649
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg) administered as 3 monthly intravitreal injections followed by pro re nata at monthly visits
Study: 26092310
Drug: Fully-liquid hexavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully-liquid hexavalent vaccine (DTaP-IPV-HB-PRP-T, Sanofi Pasteur MSD)
Study: 26092310
Drug: Non-fully liquid
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fully liquid hexavalent vaccine (DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals)
Study: 26092310
Drug: Fully-liquid hexavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully-liquid hexavalent vaccine
Study: 23545009
Drug: BCG maintenance
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG maintenance therapy with one third of usual dose (group I)
Study: 23545009
Drug: BCG maintenance
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG maintenance therapy with reduced dose and decreased number of instillations (two instead of three) (group II)
Study: 11118822
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acid (EAA) supplementation (average daily dose of 18.3 g of EAAs in pill form)
Study: 9146772
Drug: Mesalazine suppositories
Normalized name: mesalamine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine suppositories (1 g)
Study: 9146772
Drug: Hydrocortisone foam
Normalized name: hydrocortisone Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone foam (100 mg)
Study: 7816790
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (TA) for acute treatment, 200 mg at first symptoms, repeat after 2-3 hours if needed.
Study: 7816790
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (TA) for prophylactic treatment, 300 mg sustained release or 100 mg 3 times daily.
Study: 2905992
Drug: Dilevalol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 100 mg once daily for 6 weeks
Study: 29380267
Drug: SUVN-502 200
Normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUVN-502 200 mg single dose
Study: 29380267
Drug: SUVN-502 130
Normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUVN-502 130 mg once daily for 7 days
Study: 29380267
Drug: SUVN-502 100
Normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUVN-502 100 mg once daily for 14 days
Study: 29380267
Drug: SUVN-502 100
Normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUVN-502 100 mg single dose
Study: 29380267
Drug: SUVN-502 50
Normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUVN-502 50 mg once daily for 7 days
Study: 29380267
Drug: SUVN-502 50
Normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUVN-502 50 mg and 100 mg once daily
Study: 25182248
Drug: High-intensity rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity rosuvastatin (40 mg/day) for 13 months
Study: 23465742
Drug: Oestrogen patches
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen patches
Study: 18434900
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy for strict blood glucose control to normoglycemia
Study: 12517741
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) at doses of 25, 50, 125, 300, or 600 mg/wk for 20 weeks
Study: 10719857
Drug: Intrathecal bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bolus injections of baclofen
Study: 10719857
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of baclofen
Study: 3542445
Drug: Acarbose 400
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 400 mg
Study: 3542445
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg (after one week of administration)
Study: 3542445
Drug: Acarbose (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (all doses tested)
Study: 24072337
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day rosuvastatin
Study: 28669329
Drug: 20-40 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-40 mg/day rosuvastatin
Study: 23999037
Drug: Olmesartan/Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine combination (20/5mg)
Study: 22417131
Drug: Intensive long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive long-term step-down treatment program (short-term day hospital treatment followed by combined group and individual psychotherapy)
Study: 12966418
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care (SC) with concomitant chemotherapy
Study: 12966418
Drug: Cisplatin-based treatment
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based treatment
Study: 8787869
Drug: Ciprofloxacin given
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin given orally (500 mg) alone
Study: 8787869
Drug: Ciprofloxacin given
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin given orally (500 mg) plus enteral feeding (Sustacal)
Study: 8787869
Drug: Ciprofloxacin given
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin given via gastrostomy tube (500 mg crushed in 60 ml water)
Study: 8787869
Drug: Ciprofloxacin given
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin given via gastrostomy tube (500 mg crushed) plus continuous enteral formula (Jevity)
Study: 8787869
Drug: Ciprofloxacin given
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin given via jejunostomy tube (500 mg crushed)
Study: 8787869
Drug: Ciprofloxacin given
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin given via jejunostomy tube (500 mg crushed) plus continuous enteral formula (Jevity)
Study: 1454432
Drug: Cefixime (CFX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (CFX), 8 mg/kg once daily
Study: 1454432
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (PEN), 250 mg 3 times daily
Study: 3906248
Drug: Naftidrofuryl 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl 600 mg daily for six months
Study: 24827384
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 300mg tablets, two times per day for six months
Study: 20538235
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg tramadol (Group T)
Study: 20538235
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg tramadol plus 1 g of paracetamol (Group P)
Study: 18165641
Drug: PCB (Bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCB (Bevacizumab in combination with carboplatin and paclitaxel)
Study: 15906418
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg (Blosart, Julphar, UAE)
Study: 15906418
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg (Cozaar, MSD, The Netherlands)
Study: 7027708
Drug: Progestogen only
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen only (Lynestrenol 0.5 mg daily)
Study: 7027708
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (Ethinyl oestradiol 50 μg + lynestrenol 2.5 mg)
Study: 28950844
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/d for 2 weeks before surgery
Study: 27422275
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) programme, one session every 2 weeks for 10 weeks, with telephone contact every 2 weeks
Study: 27422275
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) programme
Study: 15333719
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no added gelling agent)
Study: 12587625
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ornidazole 30 mg/kg
Study: 12587625
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ornidazole 25 mg/kg
Study: 12587625
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ornidazole 20 mg/kg
Study: 12587625
Drug: Ornidazole 25
Normalized name: ornidazol
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole 25 mg/kg per day for 5 days
Study: 12587625
Drug: Metronidazole 20
Normalized name: metronidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 20 mg/kg per day for 7 days
Study: 9691361
Drug: Intravenous anti-D
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anti-D (200 micrograms)
Study: 9691361
Drug: Intramuscular anti-D
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular anti-D (200 micrograms)
Study: 9691361
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and intramuscular anti-D
Study: 2527132
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g day‐1 of crystalline fructose in divided amounts as part of their isocaloric diet
Study: 2527132
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g day‐1 of crystalline fructose
Study: 402088
Drug: 600 gm/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 gm/24 hours combination of glucose, fructose, and xylitol
Study: 31649219
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 2.4 ATA for 90 minutes in addition to conventional wound care
Study: 29281988
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate (AS)
Study: 29281988
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine (QNN)
Study: 29281988
Drug: ACT administered
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT administered
Study: 26005259
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac + oral B vitamin
Study: 26005259
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac + oral vitamin E